Literature DB >> 3262127

Spontaneous reversal of acquired autoimmune dysfibrinogenemia probably due to an antiidiotypic antibody directed to an interspecies cross-reactive idiotype expressed on antifibrinogen antibodies.

A Ruiz-Arguelles1.   

Abstract

A young man with a long history of abnormal bleeding was seen in January 1985. Coagulation tests showed dysfibrinogenemia and an antifibrinogen autoantibody was demonstrable in his serum. This antibody, when purified, was capable of inhibiting the polymerization of normal fibrin monomers, apparently through binding to the alpha fibrinogen chain. 6 mo later the patient was asymptomatic, coagulation tests were normal, and the antifibrinogen autoantibody was barely detectable. At this time, affinity-purified autologous and rabbit antifibrinogen antibodies were capable of absorbing an IgG kappa antibody from the patient's serum, which reacted indistinctly with both autologous and xenogeneic antifibrinogen antibodies in enzyme immunoassays. It has been concluded that the patient's dysfibrinogenemia was the result of an antifibrinogen autoantibody, and that later on an anti-idiotype antibody, which binds an interspecies cross-reactive idiotype expressed on anti-human fibrinogen antibodies, inhibited the production of the antifibrinogen autoantibody which led to the remission of the disorder.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3262127      PMCID: PMC303608          DOI: 10.1172/JCI113704

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  29 in total

1.  Anti-idiotypic suppression of autoantibodies to factor VIII (antihaemophilic factor) by high-dose intravenous gammaglobulin.

Authors:  Y Sultan; M D Kazatchkine; P Maisonneuve; U E Nydegger
Journal:  Lancet       Date:  1984-10-06       Impact factor: 79.321

2.  Presence of auto-anti-idiotypic antibody during the normal human immune response to tetanus toxoid antigen.

Authors:  R S Geha
Journal:  J Immunol       Date:  1982-07       Impact factor: 5.422

Review 3.  Genetically abnormal fibrinogens--strategies for structure elucidation, including fibrinopeptide analysis.

Authors:  A Henschen; M Kehl; C Southan
Journal:  Curr Probl Clin Biochem       Date:  1984

4.  Fibrinogen Petoskey: identification of a new dysfibrinogenemia characterized by altered release of fibrinopeptide A.

Authors:  D L Higgins; J A Penner; J A Shafer
Journal:  Thromb Res       Date:  1981-09-15       Impact factor: 3.944

5.  Analysis of human fibrinopeptides by high-performance liquid chromatography.

Authors:  M Kehl; F Lottspeich; A Henschen
Journal:  Hoppe Seylers Z Physiol Chem       Date:  1981-12

6.  Idiotypic network: possible explanation of seronegativity in a patient with rheumatoid arthritis.

Authors:  J L Pasquali; A Urlacher; D Storck
Journal:  Clin Exp Immunol       Date:  1984-02       Impact factor: 4.330

7.  Regulation of immunoglobulin E antibody synthesis in man by antiidiotypic antibodies.

Authors:  R S Geha; M Comunale
Journal:  J Clin Invest       Date:  1983-01       Impact factor: 14.808

8.  Suppression of rheumatoid factor synthesis by antiidiotypic antibody in rheumatoid arthritis patients with cross-reactive idiotypes.

Authors:  T Takeuchi; O Hosono; J Koide; M Homma; T Abe
Journal:  Arthritis Rheum       Date:  1985-08

9.  A naturally occurring antibody that inhibits fibrin polymerization.

Authors:  W K Hoots; N A Carrell; R H Wagner; H A Cooper; J McDonagh
Journal:  N Engl J Med       Date:  1981-04-09       Impact factor: 91.245

10.  Antiidiotypic activity in the IgM fractions of mixed cryoglobulins.

Authors:  D Geltner; E C Franklin; B Frangione
Journal:  J Immunol       Date:  1980-10       Impact factor: 5.422

View more
  5 in total

Review 1.  Intravenous immunoglobulins (IVIg) in the treatment of autoimmune diseases.

Authors:  S V Kaveri; G Dietrich; V Hurez; M D Kazatchkine
Journal:  Clin Exp Immunol       Date:  1991-11       Impact factor: 4.330

Review 2.  Immunomodulating effects of intravenous immunoglobulin in autoimmune and inflammatory diseases.

Authors:  S V Kaveri; L Mouthon; M D Kazatchkine
Journal:  J Neurol Neurosurg Psychiatry       Date:  1994-11       Impact factor: 10.154

3.  Beneficial effect of human therapeutic intravenous immunoglobulins (IVIg) in mercuric-chloride-induced autoimmune disease of Brown-Norway rats.

Authors:  F Rossi; B Bellon; M C Vial; P Druet; M D Kazatchkine
Journal:  Clin Exp Immunol       Date:  1991-04       Impact factor: 4.330

4.  An interspecies idiotope associated with the anti-cholera toxin response detected by a monoclonal auto-anti-idiotypic antibody.

Authors:  G P Lucas; C L Cambiaso; J P Vaerman
Journal:  Immunology       Date:  1993-03       Impact factor: 7.397

5.  Induction of unresponsiveness against IgA in IgA-deficient patients on subcutaneous immunoglobulin infusion therapy.

Authors:  U Sundin; S Nava; L Hammarström
Journal:  Clin Exp Immunol       Date:  1998-05       Impact factor: 4.330

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.